1227924-20-0

Basic information

• Product Name: 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one
• Synonyms: 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one
• CAS NO: 1227924-20-0
• Molecular Weight: 431.558
• Mol File: 1227924-20-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one(1227924-20-0)
• EPA Substance Registry System: 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one(1227924-20-0)

Safety Data

• Hazardous Substances Data: 1227924-20-0(Hazardous Substances Data)

Upstream product

• 1227923-94-5 6-((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)benzo[h]quinazolin-4(3H)-one 
• 5188-07-8 sodium thiomethoxide 
• 1227924-44-8 6-bromo-3-[(1S,2S)-2-hydroxycyclohexyl]benzo[h]quinazolin-4(3H)-one 
• 1227924-43-7 1-amino-4-bromo-N-[(1S,2S)-2-hydroxycyclohexyl]-2-naphthamide 
• 1227924-42-6 1-amino-4-bromo-2-naphthoic acid 
• 1268515-63-4 methyl 1-amino-4-bromo-2-naphthoate hydrobromide 
• 35092-83-2 methyl 1-amino-2-naphthoate 
• 78508-71-1 methyl 1-nitro-2-naphthoate 
• 103987-83-3 1-nitro-2-naphthoic acid 
• 881-03-8 1-nitro-2-methylnaphthalene 
• 931-15-7 (1S,2S)-trans-2-aminocyclohexanol 

Relevant articles and documents

MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate

Identification of ligands that selectively activate the M1 muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization efforts focused on addressing key physicochemical and safety properties, ultimately leading to the clinical candidate MK-7622, a highly selective positive allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer's disease.